Last edition
News about "Hygtia Therapeutics"
Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine has completed first-in-human dosing of its AI-designed NLRP3 inhibitor ISM8969 in a phase 1 clinical trial. The oral, brain-penetrant therapy is being developed with Hygtia Therapeutics for chronic neuroinflammation and CNS disorders, including Parkinson’s disease, marking a key milestone in AI-driven drug development.
Hygtia Therapeutics | 18/06/2026 | By News Bureau
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Hygtia Therapeutics | 21/01/2026 | By News Bureau | 258
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy